Finance

Mei readies Antengene to take its next steps to becoming a global biotech

Fresh off its $360 million IPO on the Hong Kong stock exchange, Shanghai’s Antengene is looking to take the next step in its evolution by building out its pipeline and launching its first drug....

SR One’s newfound freedom allows firm to increase focus on company creation

SR One’s spinout from GSK gives the newly independent VC the ability to scale up what has been a top-tier investment firm over the past decade, along with the freedom to take larger stakes...

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

Elevation raises $65M series B, names Leland CEOElevation Oncology Inc. raised $65 million in a series B round and promoted founder Shawn Leland from CBO to CEO. The venture round was led by venBio Partners and Cormorant...

Syncona enters kidney disease space with gene therapy newco Purespring

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings. On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth...

VCs back Celleron spinout with €37M to develop former Roche asset for rare joint disorder

A European VC syndicate shared Celleron’s belief that a single-asset start-up was the best place to develop emactuzumab, an asset the U.K. biotech obtained after Roche deprioritized it in 2018. The group supplied €37 million ($43.9...

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

Two years after Clarus’ acquisition by Blackstone, the life sciences investor is taking advantage of its parent company’s scale to stretch beyond its initial sweet spot. The firm that specialized in risk-sharing deals is now...

Seed financing in hand, VastBiome mines the genes of gut microbes

The founders of VastBiome have parlayed a Texas Medical Center Biodesign fellowship into support from the Illumina Accelerator, and now a $4.5 million seed round co-led by Merck Global Health Innovation Fund. Launched in Houston...

D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

The latest in a growing list of Chinese biopharma “money magnets,” D3 Bio has made its official launch with a strategy that reflects emerging trends in the sector, which include moving away from me-too pipelines, relying...

Jeito adds dry powder to invest in European innovation

French VC Jeito has added a second strategic investor, this time a little closer to home. Sanofi (Euronext:SAN; NASDAQ:SNY) invested €50 million ($59 million), marking the pharma’s first investment into...

Nov. 11 Quick Takes: Adagio raises $80M for COVID-19 antibody; plus venture investments for Congenica, CoImmune, Trailhead, Doer Biologics, Protomer and more

GV leads $80M series B for COVID antibody play AdagioAdagio Therapeutics Inc. raised $80 million in a series B round led by GV, with backing from existing investors Polaris Partners, Mithril Capital, Fidelity Management &...

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

After raising nearly HK$4 billion ($514.3 million) in the year’s largest biotech IPO thus far, Yantai-based RemeGen gained 34% in its first trading day, finishing Monday’s session with a valuation of $4.3 billion. The deal tops...

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

Biogen tumbles after aducanumab panelAfter Friday’s FDA advisory committee meeting for Alzheimer’s therapy Aduhelm aducanumab, shares of Biogen Inc. (NASDAQ:BIIB) sank $92.64 (28%) to $236.26 Monday, obliterating nearly $14.3 billion of the company’s market value. Panelists not...

Apollomics anchors investor base in Asia with $124M raise as it readies for its next phase of growth

Apollomics has shored up its Asian investor base with a $124 million series C round that provides the oncology company with flexibility to advance its pair of lead compounds while continuing to hunt for...

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics Co. Ltd. (HKEX:2126) fell HK$1.80 to HK$22 after raising HK$2.3 billion ($300 million) in an IPO. Bristol Myers Squibb...

Data Byte: at $1.9B valuation, Atea leads this week’s IPOs

Atea led the pack of IPOs priced in the final week before the U.S. election, trading up 26% to $30.34 on its first day of trading Friday after raising $300 million. The upsized offering valued Jean-Pierre...